{"name":"Novel Anti-Infective Technologies, LLC","slug":"novel-anti-infective-technologies-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNUzlEc2RhU2hyWEV6S2M4a3A1S1pWQ2RXdFpVQTZZZ1ptbEs3VUMwVDVTQm9keXMwRHRrbFdybVJ6TXl1S2Q5NGpodERqZjhkS3hnOWlZMjFjM1lpVlVXSVR3T2pnc1ptUTlmVFhpci1VY0l6Q0xLQkh3a0p0eUxjU0lxOHl2cXM3SGVzMw?oc=5","date":"2026-04-02","type":"deal","source":"IndexBox","summary":"Biogen Acquires Apellis for $5.6B, Shares Dip | Strategic Immunology Move - News and Statistics - IndexBox","headline":"Biogen Acquires Apellis for $5.6B, Shares Dip | Strategic Immunology Move - News and Statistics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE9idXU3RjBUNHp1eTFJRll6c1E4QVhaVEhHNXNQWmlmQ0F3SXBGc1FCbXo0cGNZVzBFQ3VwTHZZVFZnNGJoU3BwRkkybkVmdDV5eWRVcDhiRXhtQlpZanQwWlJiMGhXdlRIR0JaT0p4TmUxQTFF?oc=5","date":"2026-01-09","type":"pipeline","source":"VISTA.Today","summary":"Malvern-Based Venatorx Pharmaceuticals Scales Down of Operations - VISTA.Today","headline":"Malvern-Based Venatorx Pharmaceuticals Scales Down of Operations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBpSHM2YlhaVUVnYnNpTndYdkpqbzVzN19xSU5RX2pIeVkyRUtZNWEtTmxBU0plWDJSZVJpVkh4Q0VBQkZockdDaGtjSVlqT2NKLUl3VUJYeHBZVzNhcmU4?oc=5","date":"2025-03-05","type":"pipeline","source":"nature.com","summary":"Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines - nature.com","headline":"Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxOa08tM3A4MU54aDNTNmhyYVBPcVNTOWNSVWk5dzZMeHp0TnpwRHFvZEtXc1QzaGFETU81TEo0OVRqYmNoNkNTT2dnNjBRM0hnRzhjbDVyaUd3S01LelB0WG0yRk5lQjR0ZEdpaFpsTVp1R3hWdGFxb2lTbjFoemFMa2NwZTVQUEd2MjdTZWJLSlN0ZF9KV09XeVZWOU55SWxQcVB5aGQ1a09CT3d2VlY4dUFqMFFKMmMtSF9iZzE5eGNxQnR2dlY0c042MmJzUHhlTUNNODMySkJGX1g4V1ZMeTk1Umw?oc=5","date":"2024-08-30","type":"pipeline","source":"PR Newswire","summary":"Global Anti-Infective Drugs Market is Projected to Cross ~USD 175 Billion by 2030 | DelveInsight - PR Newswire","headline":"Global Anti-Infective Drugs Market is Projected to Cross ~USD 175 Billion by 2030 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygJBVV95cUxPUm1aTXBsY2RMclMxUG1MRTUzMUNJYVMxSml5VFlTOS1fUW5aZ3JKZlFMVF9memtsRlhaTHU2QjVGbGJiN2ItRVZRM3UyY1Jfd1pzclJVWXlXZDZyLVkyQXZQOHZoT2ZRdzBMLVpTb0lUQXRieGcwLWJndERGYldwVjExbWNUUUN6bFViTGdfbk9YWHlaMmpyc21UT1g2Yi04a1Y3ZHFoVVo3QjNWOVhqcW9vUDFnTUROeUxuMjRqWXZfRkozUnpNRVdMZVV4ZzB4QWJhY2dkcU04NWx0eUxBWlZ3YTJhc3diLUN6dTRCSEd3NVA3QzBpTzk0NnVnNFJGeURGSlhMb3VXcHBnTnJHSlhocDdtQThsdXptVmhhZXYxeTJWbnVueDdMc1J5RFhjLTZsd0NCUjNqXzJUUU1DOXRoa1d4X2c1THc?oc=5","date":"2022-03-03","type":"earnings","source":"businesswire.com","summary":"ArrePath Announces $20 Million Seed Financing to Advance its Machine Learning-based Platform for Discovery of Novel Anti-infectives Addressing Antimicrobial Resistance - businesswire.com","headline":"ArrePath Announces $20 Million Seed Financing to Advance its Machine Learning-based Platform for Discovery of Novel Anti","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}